Protocols: Private equity buy-in values inVentiv at $3.8B; Celgene denies charity scheme allegations
The CRO inVentiv Health has bagged a buy-in from Advent Health that values the company at $3.8 billion. Advent now becomes a co-owner of the company with Thomas H. Lee Partners and inVentiv will drop its plans for an IPO.
Seattle Genetics and its partner Takeda say they hit their primary endpoint in a Phase III study of Adcetris for patients with cutaneous T-cell lymphoma. The companies called the data “highly statistically significant” in the rate of objective responses which lasted at least four months. Seattle Genetics’ share price, though, barely budged.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.